The Invisible Burden: Mental Health Professionals Call for Specialized Support for the "Previvor" Community

By Investigative Health Correspondent
Published: June 30, 2026

NEW YORK — As genetic testing becomes a standard component of preventative medicine, a new demographic of patients is emerging within the healthcare landscape: the "previvor." These individuals, who carry a genetic predisposition to cancer but have not yet received a diagnosis, face a unique set of psychological challenges that the traditional mental health system is often ill-equipped to handle.

In a comprehensive report released this week, Laura Schneebaum, LMHC-D, LPC, NCC, a prominent therapist specializing in hereditary cancer, highlighted a startling gap in clinical care. Despite the rapid advancement in identifying genetic markers like BRCA1 and BRCA2, the emotional infrastructure required to support those living in the "waiting room" of a potential diagnosis remains critically underdeveloped.

Main Facts: The Psychological Weight of Genetic Predisposition

The term "previvor"—a portmanteau of "pre-disposition" and "survivor"—was coined to describe individuals living with a high risk of cancer. While medical interventions such as prophylactic surgeries (mastectomies and oophorectomies) and high-intensity surveillance are well-documented, the mental health implications are frequently sidelined.

According to Schneebaum, previvors often navigate a landscape of "unseen" trauma. "It baffles me that so few mental health professionals are talking about these unique challenges," Schneebaum stated. "Knowing you are at high risk can leave you feeling anxious, alone, and isolated. It is a state of perpetual hyper-vigilance that can be as taxing as the disease itself."

The core of the previvor experience is defined by several key psychological stressors:

Medical Trauma and "Scanxiety": The cyclical nature of screenings—often occurring every six months—creates a "boom and bust" cycle of anxiety.
Decision Fatigue: Previvors must make life-altering decisions regarding organ removal, often in their 20s or 30s, impacting their fertility, body image, and sexual health.
Survivor Guilt: Many previvors have watched family members succumb to the very disease they are trying to outrun, leading to complex grief and guilt.
Identity Crisis: Living as a "patient-in-waiting" complicates one’s sense of self, as the body is viewed through the lens of potential betrayal.

Chronology: From Genetic Discovery to the Previvor Movement

The journey toward recognizing previvor mental health has been decades in the making, parallel to the evolution of genomic medicine.

1994–1995: The discovery of the BRCA1 and BRCA2 genes revolutionized oncology, allowing doctors to identify individuals at an 80% lifetime risk of breast cancer.
Early 2000s: The term "previvor" gained traction in online forums as individuals sought a label that acknowledged their unique status—neither "healthy" in the traditional sense nor "cancer patients."
2013: The "Angelina Jolie Effect." The actress’s public disclosure of her prophylactic double mastectomy brought global attention to hereditary cancer, leading to a surge in genetic testing.
2020–2025: Genetic testing became ubiquitous and more affordable. Direct-to-consumer kits and expanded panels (including CHEK2, PALB2, and Lynch Syndrome) significantly increased the number of identified previvors.
2026 (Present): The focus shifts from the identification of risk to the management of the person. Experts like Schneebaum and organizations like Sharsheret are now advocating for a "Whole-Patient" approach that prioritizes psychological resilience alongside surgical prevention.

Supporting Data: The Scale of the Crisis

Statistical evidence underscores the necessity of specialized mental health intervention. Data from the National Cancer Institute and various hereditary advocacy groups reveal the following:

Prevalence: Approximately 1 in 40 Ashkenazi Jews carries a BRCA mutation, a rate significantly higher than the general population (1 in 400). This has made the Jewish community a focal point for organizations like Sharsheret.
Psychological Impact: A 2025 study indicated that up to 45% of previvors report clinically significant levels of anxiety, and 30% exhibit symptoms of Post-Traumatic Stress Disorder (PTSD) related to their family medical history.
The Counseling Gap: While 90% of individuals receive genetic counseling before testing, fewer than 15% are referred to specialized mental health therapy after testing positive for a mutation.
Surgical Trends: The rate of bilateral prophylactic mastectomies has increased by over 200% in the last decade among mutation carriers, yet post-operative psychological support remains a secondary consideration in many surgical centers.

Official Responses: Advocacy in the "Waiting Room"

In response to this growing need, Sharsheret, a leading national organization supporting Jewish women and families facing breast and ovarian cancer, has expanded its mental health initiatives. Their latest program, "The Waiting Room," is designed specifically for those navigating the uncertainty of screenings and results.

"Sharsheret is here for you in the Waiting Room as you face your fear of the unknown," the organization stated. The initiative, supported by generous contributions from anonymous donors and pharmaceutical giants AstraZeneca and Merck, provides a digital and physical sanctuary for those at high risk.

The corporate involvement of AstraZeneca and Merck signals a shift in the pharmaceutical industry’s approach. These companies, traditionally focused on oncology therapeutics, are increasingly investing in the "pre-patient" space, recognizing that the journey of a cancer survivor often begins long before a tumor is detected.

Laura Schneebaum’s clinical framework for previvors offers four personalized strategies to mitigate the psychological toll:

Normalization of the Previvor Identity: Encouraging patients to accept that their anxiety is a rational response to an irrational situation.
Community Integration: Moving away from isolation by connecting with others who share the same genetic burden.
Body Reclaiming: Using therapy to view the body as a source of strength rather than a "ticking time bomb."
Boundaried Information Consumption: Managing the "information overload" that often comes with genetic research and social media.

Implications: The Future of Proactive Mental Health

The rise of the previvor movement has profound implications for the future of healthcare. As we move deeper into the era of personalized medicine, the definition of a "patient" is being rewritten.

1. The Need for Specialized Training

There is an urgent demand for mental health professionals to be trained in "Genetic Literacy." Therapists must understand the difference between various mutations, the nuances of surgical options, and the specific cultural contexts (such as the Ashkenazi Jewish experience) that influence a patient’s decisions.

2. Policy and Insurance Reform

Currently, many insurance providers cover the cost of genetic testing and prophylactic surgery but provide limited coverage for the long-term mental health counseling required to process these life-altering events. Advocacy groups are expected to lobby for "Genetic Mental Health Parity" in the coming legislative sessions.

3. Ethical Considerations in Family Planning

The previvor status often impacts reproductive choices. With the rise of Preimplantation Genetic Testing (PGT-M), previvors are now making complex ethical decisions about whether to pass their mutations to the next generation. This adds another layer of psychological complexity that requires expert navigational support.

4. Shifting the Medical Paradigm

The medical community is beginning to realize that "curing" cancer is not the only goal; "preventing" the trauma associated with the risk of cancer is equally vital. The collaboration between therapists like Schneebaum, organizations like Sharsheret, and the pharmaceutical industry suggests a future where the mind and the genome are treated with equal urgency.

Conclusion

As Laura Schneebaum notes, there is no "one-size-fits-all" solution for the previvor. However, by bringing the conversation into the light, the medical community can ensure that no one has to sit in the "waiting room" alone. The invisible burden of genetic risk is finally becoming visible, and with that visibility comes the opportunity for healing long before a diagnosis ever occurs.

About Sharsheret:
Sharsheret is a national non-profit organization improving the lives of Jewish women and families living with or at increased genetic risk for breast or ovarian cancer through personalized support and community educational programs.

About Laura Schneebaum:
Laura Schneebaum, LMHC-D, LPC, NCC, is a licensed therapist specializing in the intersection of mental health and hereditary cancer. Her work focuses on empowering previvors and survivors through clinical excellence and advocacy.